Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
News
Market Highlights: US stocks dip as debt ceiling disaster looms; and 5 ASX small caps to watch on Friday
Health & Biotech
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Health & Biotech
PharmAust patients successfully complete first dosing level for Motor Neurone Disease trial
Health & Biotech
PharmAust is preparing for a successful Phase 2 completion
Health & Biotech
Stock Insiders: PharmAust’s subsidiary Epichem generates $3.5m in sales in FY2022
Health & Biotech
PharmAust banks R&D tax incentive for innovative research as monepantel clinical trials progress
Health & Biotech
PharmAust’s MND trial completes enrolment of first patient cohort
Stockhead TV
Year in Review: PharmAust (ASX:PAA) with general manager, Fiona Milner
Health & Biotech
Owners of dogs in PharmAust’s Phase 2 trial are very grateful with results
News
Pampered pooches: Which ASX stocks are riding the ‘humanisation of pets’ trend?
News
ASX Quarterlies: Fintechs stand out as Biotechs press forward with clinical trials
Health & Biotech
PharmAust doses first patient in Phase 1/2 trial of monepantel treating Motor Neurone Disease
Health & Biotech
PharmAust recruits first dog patient in the US, aims to close out Phase 2 canine trial faster
Health & Biotech
PharmAust says MPL can double the life expectancy of dogs with cancer; US trials to begin
Health & Biotech
Broker JP Equity says PharmAust has multiple avenues to $US 1 billion+ success
Health & Biotech
Here are the Top 10 crucial trials coming up for ASX biotechs in 2022
News